Prediction Model for the Recanalization OuTcome Evaluation of Ischemic Stroke Using Multimodal CT
NCT ID: NCT03670862
Last Updated: 2021-09-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
862 participants
OBSERVATIONAL
2019-01-01
2021-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke
NCT01656785
Early Neurological Trajectory and Clinical Outcomes in Brain Acute Ischemic Stroke
NCT06170086
Predictors and Prognostic Factors on the Acute Ischemic Stroke
NCT03122002
Blood Proteome Profiling Identifies Biomarkers in Ischemic Stroke
NCT06729385
Comprehensive Assessment of Atherosclerotic Ischemic Stroke Risk and Development of a Prediction Model
NCT06315153
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Imaging protocols:
CT scan protocols: Non-contrast computed tomography(NCCT) , computed tomography angiography(CTA), computed tomography perfusion(CTP)
Contrast agent:
CTA: Omniscan 40-50ml, 5ml/s; saline solution 50ml, 5ml/s
CTP: Omniscan 50ml, 5ml/s; saline solution 50ml, 5ml/s
Imaging evaluation:
CTA was reviewed and stenosis or occlusive lesions were identified. Parameter maps including cerebral blood flow, cerebral blood volume, mean transit time, the time to the maximum of the residue function derived from CTP were processed by the software Rapid to quantitatively assess infarct core volume and mismatch.
Multiphase CTA was extracted from CTP to evaluate the collateral circulation.
Treatment:
Intravenous recombinant tissue plasminogen activator(rtPA), endovascular therapy, and conventional treatment including neuroprotection, anti-platelet, and statin according to the guideline.
Follow up:
Modified Rankin Scale(mRS) was obtained at 90 days after symptom onset. An imaging follow-up was also recommended within 30 days after symptom onset.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
stroke
Ischemic stroke patients with sympton onset in 24 hours
CT
Non-contrast computed tomography , computed tomography angiography, computed tomography perfusion imaging
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CT
Non-contrast computed tomography , computed tomography angiography, computed tomography perfusion imaging
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All CT examination performed according to study protocol
* Signed informed consent obtained from the patient or patient's legally authorized representative
Exclusion Criteria
* Pre-existing medical, the neurological, or psychiatric disease that would confound the neurological, functional, or imaging evaluations
* Pregnancy
* Known allergy to iodine previously refractory to pretreatment medications
* Renal Failure (serum creatinine \> 2.0 or Glomerular Filtration Rate \< 30)
* History of severe kidney disease as an adult, including tumor or transplant surgery, or family history of kidney failure
* Severe cardiac insufficiency
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese PLA General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xin Lou
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xin Lou, M.D.,Ph.D.
Role: STUDY_CHAIR
Chinese PLA General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PROTECT-ChinaPLAGH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.